GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » Beneish M-Score

IDEXX Laboratories (IDEXX Laboratories) Beneish M-Score : -2.43 (As of Apr. 25, 2024)


View and export this data going back to 1991. Start your Free Trial

What is IDEXX Laboratories Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.43 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for IDEXX Laboratories's Beneish M-Score or its related term are showing as below:

IDXX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.86   Med: -2.43   Max: -2.16
Current: -2.43

During the past 13 years, the highest Beneish M-Score of IDEXX Laboratories was -2.16. The lowest was -2.86. And the median was -2.43.


IDEXX Laboratories Beneish M-Score Historical Data

The historical data trend for IDEXX Laboratories's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Beneish M-Score Chart

IDEXX Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.39 -2.43 -2.26 -2.16 -2.43

IDEXX Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.16 -2.21 -2.24 -2.30 -2.43

Competitive Comparison of IDEXX Laboratories's Beneish M-Score

For the Diagnostics & Research subindustry, IDEXX Laboratories's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Beneish M-Score falls into.



IDEXX Laboratories Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of IDEXX Laboratories for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9922+0.528 * 0.995+0.404 * 0.9096+0.892 * 1.0872+0.115 * 1.032
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9751+4.679 * -0.018856-0.327 * 0.6944
=-2.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $530 Mil.
Revenue was 901.601 + 915.527 + 943.63 + 900.195 = $3,661 Mil.
Gross Profit was 526.167 + 547.982 + 572.85 + 542.971 = $2,190 Mil.
Total Current Assets was $1,495 Mil.
Total Assets was $3,260 Mil.
Property, Plant and Equipment(Net PPE) was $818 Mil.
Depreciation, Depletion and Amortization(DDA) was $115 Mil.
Selling, General, & Admin. Expense(SGA) was $902 Mil.
Total Current Liabilities was $952 Mil.
Long-Term Debt & Capital Lease Obligation was $723 Mil.
Net Income was 194.521 + 212.231 + 224.236 + 214.054 = $845 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 249.851 + 272.433 + 200.314 + 183.912 = $907 Mil.
Total Receivables was $491 Mil.
Revenue was 828.568 + 841.661 + 860.546 + 836.549 = $3,367 Mil.
Gross Profit was 484.927 + 506.626 + 514.032 + 498.753 = $2,004 Mil.
Total Current Assets was $1,101 Mil.
Total Assets was $2,747 Mil.
Property, Plant and Equipment(Net PPE) was $768 Mil.
Depreciation, Depletion and Amortization(DDA) was $112 Mil.
Selling, General, & Admin. Expense(SGA) was $851 Mil.
Total Current Liabilities was $1,236 Mil.
Long-Term Debt & Capital Lease Obligation was $796 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(529.528 / 3660.953) / (490.903 / 3367.324)
=0.144642 / 0.145784
=0.9922

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2004.338 / 3367.324) / (2189.97 / 3660.953)
=0.595232 / 0.598197
=0.995

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1495.254 + 817.676) / 3259.925) / (1 - (1101.477 + 768.092) / 2746.765)
=0.290496 / 0.319356
=0.9096

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3660.953 / 3367.324
=1.0872

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(111.9 / (111.9 + 768.092)) / (114.908 / (114.908 + 817.676))
=0.12716 / 0.123215
=1.032

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(901.891 / 3660.953) / (850.753 / 3367.324)
=0.246354 / 0.25265
=0.9751

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((722.554 + 951.547) / 3259.925) / ((795.626 + 1235.803) / 2746.765)
=0.51354 / 0.739571
=0.6944

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(845.042 - 0 - 906.51) / 3259.925
=-0.018856

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

IDEXX Laboratories has a M-score of -2.43 suggests that the company is unlikely to be a manipulator.


IDEXX Laboratories Beneish M-Score Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEXX Laboratories (IDEXX Laboratories) Business Description

Address
One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Executives
James F Polewaczyk officer: Corporate Vice President IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky director, officer: President and CEO ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith officer: Executive Vice President C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers director, officer: President & CEO IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane officer: Executive Vice President C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt director CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin director 7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley director C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak director C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg officer: EVP, GC & Corporate Secretary EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek director 6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451